Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: PTCL patient-derived models genomic characterization

PROVIDER: PRJNA1214670 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32090300_1.fastq.gz	Fastqsanger.gz
	SRR32090300_2.fastq.gz	Fastqsanger.gz
	SRR32090400_1.fastq.gz	Fastqsanger.gz
	SRR32090400_2.fastq.gz	Fastqsanger.gz
	SRR32090500_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 566

Similar Datasets

Human and Mouse

Project description:PTCL patient-derived models genomic characterization

| PRJNA1198080 | ENA

Project description:Single-Cell RNA-Seq of PTCL-derived models

| PRJNA1218277 | ENA

Homo sapiens

Project description:Genomic Characterization of Ovarian Cancer Patient-derived Organoids

| PRJNA810525 | ENA

Array-CGH for cell lines derived from paired primary and metastatic tumor

Project description:Characterization of DNA copy number changes in cell line derived from patient using DNA microarray-based comparative genomic hybridization method. Our study identified genomic alterations between primary and metastatic tumor within a single individual

2017-07-21 | GSE84674 | GEO

Transcription profiling of biopsy samples from peripheral T-cell lymphoma (PTCL)

Project description:Molecular signatures to improve diagnosis in PTCL and prognostication in angioimmunoblastic T-cell lymphoma (AITL). Gene expression profiling of PTCL patient samples was performed to investigate whether molecular signatures can be used to identify distinct entities of PTCL. Gene expression profiling was performed on PTCL and natural-killer cell lymphoma (NKCL) to define molecular classifiers for the more common entities of PTCL, to identify unique entities within PTCL-U, to elucidate unique tumor and microenvironmental interactions and oncogenic pathways in AITL, and to construct a molecular prognosticator for AITL.

2010-02-27 | E-GEOD-19069 | biostudies-arrayexpress

Metabolic Characterization of Patient-derived Xenograft Models of Clear Cell Renal Cell Carcinoma Transcriptomic Analysis

Project description:To investigate the metabolic characterization difference of patient-derived xenograft models in transcriptome level.

2022-09-24 | GSE213857 | GEO

Project description:Establishment and characterization of testicular cancer patient-derived xenograft (PDX) models

| PRJNA639088 | ENA

Establishment and characterization of testicular cancer patient-derived xenograft (PDX) models

Project description:Establishment and characterization of testicular cancer patient-derived xenograft (PDX) models

| PRJNA649229 | ENA

Molecular signatures in peripheral T-cell lymphoma (PTCL)

2010-02-08 | GSE19069 | GEO

SMARCB1 loss defines a novel PTCL-NOS subtype displaying an immunosuppressive TME susceptible to HDAC inhibitors [single-cell RNA-seq]

Project description:Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) are aggressive and heterogeneous tumors with poor outcome and scarce genetic characterization. We analyzed by immunohistochemistry tumor tissue of adult and pediatric PTCL-NOS patients and discovered frequent loss of SMARCB1 positivity, mostly associated with pediatric cases (45%). Using a genetically engineered mouse model (PTCL-NOSSmarcb1-) and single-cell RNA sequencing, we investigated the transcriptional landscape of this Smarcb1-negative PTCL-NOS tumor and the functional interactions between tumor and tumor microenvironment (TME). We unrevealed an immunosuppressive, exhausted and proinflammatory TME, characterized by high myeloid cell infiltration (predominantly myeloid derived suppressor cells, MDSC) and reduced lymphoid infiltration. In addition, using a multidrug epigenetic screen in vitro, we identified histone deacetylase inhibitors (HDACi) as promising agents against PTCL-NOSSmarcb1-. Treatment of PTCL-NOSSmarcb1- mice with SAHA, a pan-HDACi, triggered TME remodelling, promoting the replenishment of T- and B-cell compartments and the limitation/reversion of the exhaustion phenotype. In conclusion, we have identified a novel PTCL-NOS subtype characterized by the loss of SMARCB1 at pediatric ages, presenting an exhausted and immunosuppressive TME. Administration of SAHA reshaped the TME increasing lymphoid cells recruitment into the tumor bed, turning the tumor from cold to hot. These results provide the rationale for further investigations based on combination therapies.

2024-07-18 | GSE190274 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data